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Prediction of survival for patients with metastatic breast cancer is often inaccurate and may be helped by new biological parameters.
Tumour growth being angiogenesis-dependent, it has been hypothesised that the assessment of angiogenic factor production might
reflect the clinical behaviour of cancer progression. This study was designed to investigate the clinical significance of vascular
endothelial growth factor (VEGF) and interleukin 6 (IL-6) in hormone-refractory metastatic breast cancer. Serum and plasma
concentrations of VEGF and serum concentration of IL-6 were measured in 87 patients with a fully documented history of metastatic
breast cancer using an enzyme-linked immunoassay. All patients had detectable levels of VEGF, whereas 39% patients had detectable
serum levels of IL-6. There was a positive correlation between IL-6 levels and the theoretical VEGF load of platelets (Po0.001). The
presence of high levels of serum IL-6, but not VEGF, was significantly correlated to a shorter survival. In a multivariate analysis along
with clinical prognostic parameters, serum IL-6 was identified as an independent adverse prognostic variable for overall survival
(Po0.001). These results indicate that serum IL-6 levels correlate to poor survival in patients with hormone-refractory metastatic
breast cancer. Vascular endothelial growth factor serum and plasma levels are not useful indicators of prognosis for these patients.
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Although several prognostic factors for survival have been
identified in metastatic breast cancer patients, the prognosis of
individual patients frequently fails to confirm published predic-
tions (Honig, 1996). Additional biological parameters are therefore
required to gain more accurate insight into the outcome of
metastatic breast cancer patients. Recent cancer research has
highlighted the importance of tumour neovascularisation in the
initial and metastatic growth of cancer (Hanahan and Folkman,
1996) and there is solid evidence supporting the evaluation of
tumour angiogenesis for prognosis in cancer patients (Poon et al,
2001). Thus, the assessment of angiogenic factor production may
allow a better estimation of survival for patients with metastatic
breast cancer.
The vascular endothelial growth factor (VEGF) is one of the
most potent and specific angiogenic molecules. In breast cancer,
VEGF expression in the primary tumour appears to be signifi-
cantly correlated with relapse-free survival (Gasparini, 2000).
Elevated serum levels of VEGF have been found in metastatic
cancer patients. These levels have been correlated to the clinical
course of the disease in several tumour types (Poon et al, 2001;
Ugurel et al, 2001; Molica et al, 2002). As most serum VEGF is
released from platelets during blood clotting, it has been suggested
that plasma VEGF may be a better reflection of ongoing angiogenic
activity, although this assumption has been challenged (Banks et al,
1998; Salven et al, 1999a; Wynendaele et al, 1999; George et al,
2000). To date, plasma VEGF has not been shown to be a better
prognostic factor than serum VEGF in any solid tumour (Werther
et al, 2002).
Interleukin 6 (IL-6) is a pleiotropic cytokine produced by a
variety of cell types, including endothelial cells and normal
haematopoietic cells (Kishimoto et al, 1995). High IL-6 serum
levels are correlated with shorter survival in patients with
haematological malignancies, renal cell carcinoma and prostate
cancer (Blay et al, 1992; Nakashima et al, 2000). Recent
publications have highlighted the importance of IL-6 in the
regulation of VEGF production. Interleukin 6 expression is
induced by hypoxia and, in turn, is able to upregulate VEGF
transcription via a specific response element present upstream of
the transcription initiation site of VEGF (Cohen et al, 1996; Yan
et al, 1997). Furthermore, IL-6 has been shown to correlate with
platelet count and platelet VEGF content. As circulating VEGF is
mostly transported by platelets, IL-6 could be regarded as an
indirect angiogenic factor that facilitates the production and the
distribution of VEGF to metastatic sites (Salgado et al, 1999, 2002;
Vermeulen et al, 1999).
The present study was undertaken to investigate connections
between serum VEGF, plasma VEGF and serum IL-6 levels in
metastatic breast cancer patients and evaluate their potential
relation to the clinical outcome.
PATIENTS AND METHODS
Patients
Serum and matched plasma samples from 73 patients were used in
this study. A serum sample without matched plasma sample was Revised 7 January 2003; accepted 10 March 2003
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yavailable for an additional 14 patients. All patients had a fully
documented history of metastatic breast cancer and were treated in
our institution between January 1995 and November 2000. Serums
and EDTA plasma samples were collected after obtaining informed
consent, aliquoted and stored at  801C. The characteristics of the
patients are shown in Table 1. Median age was 54 years (range 26–
86). In all, 41 patients (47%) had received adjuvant chemotherapy
as part of initial therapy. The median disease-free interval (from
first diagnosis to recurrence) of the 87 patients was 32 months
(range 0–19 years). For the 41 patients who had received adjuvant
chemotherapy, there was at least a 4-month interval between the
last course of adjuvant chemotherapy and blood sampling. All
patients in this series had metastatic disease refractory to hormone
therapy, that is, receptor-negative for both oestrogen and
progesterone or progressive after hormone therapy. In all, 61
patients had previously received first-line chemotherapy for
metastatic disease. Most patients (75%) had metastatic disease at
multiple sites and 59% had liver involvement.
Serum analysis
Serum and EDTA plasma samples were kept frozen at  801C, then
thawed shortly before determination of VEGF and IL-6 levels.
Commercially available immunoassay kits were used according to
the manufacturers’ instructions. Vascular endothelial growth
factor levels were determined with the Quantikine
s human VEGF
immunoassay kit from R&D system (R&D System, Minneapolis,
MN, USA); IL-6 levels were determined with the Human IL-6
Enzyme Immunoassay kit from Immunotech (Immunotech,
Marseille, France). Both assays employ the quantitative sandwich
enzyme immunoassay technique. All plasma and serum level
determinations were performed in triplicate. The theoretical
detection limits of the immunoassay were 5pgml
 1 for VEGF
and 8pgml
 1 for IL-6.
Statistical analysis
Statistical analyses were carried out according to the procedures of
the SPSS
s package 8.0 (Chicago, USA, 1999). Patients’ character-
istics were compared using Student’s t-test for quantitative
variables. Correlation analysis with the Pearson test was used to
study relations between continuous variables. Survival data,
considered from the day of sampling to the time of death or the
time of last follow-up, were assessed by means of the Kaplan–
Meier method. Univariate analyses of survival times were
performed using the log rank test. For this analysis, we tested
three different threshold values for each of the two variables: the
lowest quartile, the median and the highest quartile. In addition,
we tested the detection limit for IL-6 and two threshold values
previously reported as relevant for VEGF (Salven et al, 2000;
Ugurel et al, 2001). The Cox proportional hazard regression model
was used to identify independent prognostic factors for survival.
The variables introduced in the model were prognostic factors
commonly accepted for metastatic breast cancer and parameters
previously identified as significantly related to survival in the
univariate analysis.
RESULTS
Serum and plasma levels of VEGF and serum levels of IL-6
Serum VEGF was detectable in all 87 patients. The median serum
VEGF level was 302pgml
 1 (range 31–3183pgml
 1). Confirming
previously published results (Salgado et al, 1999), high serum
VEGF levels were correlated with high platelet counts in our
patients (r¼0.6; Po0.001). As previously described, we estimated
the theoretical VEGF load of platelets as the ratio of VEGF serum
concentration on platelet number (Banks et al, 1998; Salgado et al,
1999; Salven et al, 1999a). As calculated, the median platelet VEGF
concentration was 1.5pg10
 6 platelets (range 0.2–9.6pg10
 6
platelets).
Plasma VEGF levels were evaluated in matched plasma samples
available for 73 patients. The median plasma VEGF level was
177pgml
 1 (range 0–1447pgml
 1). Plasma VEGF was not
detectable in one patient (1.3%). There was a strong correlation
between serum and plasma VEGF concentrations (r¼0.74,
Po0.001, Figure 1), and between plasma VEGF and platelet count
(r¼0.5; Po0.001).
Interleukin-6 serum levels, assessed on 80 patients, were
detectable in 31 (39%), with a median of 30pgml
 1 when
detectable (range 8.2–211pgml
 1). In the following analysis,
IL-6 serum level is considered to be 0pgml
 1 for the 49 patients
whose serum level was below the detection limit (8pgml
 1). The
correlation between IL-6 levels and platelet counts was not
statistically significant (r¼ 0.08, P¼0.5), neither was the
correlation between serum IL-6 and serum VEGF levels (r¼0.16,
P¼0.15) or plasma VEGF levels (r¼0.07, P¼0.5). On the other
hand, we found a positive correlation between serum IL-6 levels
and the theoretical VEGF load of platelets (r¼0.54, Po0.001). The
mean VEGF load of platelets was 2.8pg10
 6 platelets for the 15
patients whose serum IL-6 level was above 30pgml
 1, vs
1.7pg10
 6 platelets for the 65 patients whose serum IL-6 level
was below 30pgml
 1 (P¼0.01). With regard to disease extension,
we did not find any correlation between IL-6 levels and liver
involvement or IL-6 levels and the number of metastatic sites.
Prognostic value of IL-6 and VEGF for overall survival
At the time of analysis, the median survival of the entire patient
population was 10 months from the date of sampling. The actuarial
survival rates were 44 and 25% at 12 and 24 months, respectively.
Serum IL-6 levels correlated with survival. Survival differences
were statistically significant for three of the four cutoff values
Table 1 Patient characteristics
Characteristics No. of patients Percent
Entered on study 87 100
Age (years)
Median 54
Range 26–86
PS
0–1 55 63
2–4 32 37
Receptor status
ER Positive 58 67
ER Negative 23 26
Unknown 6 7
Adjuvant chemotherapy
Received 41 47
Not received 46 53
Prior chemotherapy for metastatic disease
Received 61 70
Not received 26 30
Disease-free interval
o24 months 49 56
424 months 38 44
Metastatic site
Liver 51 59
Lung 45 48
One or two 49 56
Three or more 38 44
LDH
p1 normal 25 29
41 normal 62 71
PS¼performance status; ER¼estrogen receptor; LDH¼lactate dehydrogenase.
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ytested in univariate analysis: detection limit (8pgml
 1, P¼0.07),
lowest quartile (13pgml
 1, P¼0.02), median (30pgml
 1,
P¼0.05) and highest quartile (55pgml
 1, Po0.001). High serum
IL-6 levels were associated with a particularly poor survival: A
serum IL-6 level over 13pgml
 1 was associated with a median
survival time of 4 months, whereas patients with serum IL-6 level
below 13pgml
 1 had a median survival time of 13 months. The
median survival time of the eight patients with serum IL-6 levels
above the highest quartile (55pgml
 1) was 1 month, vs 12 months
for the 72 patients with IL-6 levels below 55pgml
 1 (Figure 2).
In contrast, no correlation between survival and serum or
plasma VEGF levels was observed. Different threshold values of
serum VEGF levels have been tested, particularly 363 and
462pgml
 1 as those values were recently described as being
correlated to survival in melanoma and lymphoma (Salven et al,
2000; Ugurel et al, 2001). In this series, the median survival was 9
months for patients with VEGF levels lower than 462pgml
 1 and
13 months for other patients (P¼0.9, Figure 3). We then tested
three different threshold values to assess the impact of the
theoretical VEGF load of platelets on survival. None of them made
it possible to discriminate a group of good or bad prognosis
patients. The same negative results were obtained when different
threshold values were tested with plasma VEGF levels: lowest
quartile (92pgml
 1, P¼0.8), median (177pgml
 1, P¼0.9) and
highest quartile (375pgml
 1, P¼0.63).
Multivariate analysis
A multivariate analysis of prognostic factors using the Cox model
was performed on this series of 87 patients with metastatic breast
cancer. The variables introduced in the Cox regression model were
the prognostic parameters previously described as being relevant
in metastatic breast cancer. These included performance status
(0–1 vs 2–3), liver involvement (present vs absent), lung
involvement (present vs absent), adjuvant chemotherapy (received
vs not received), LDH level (pnormal vs 4normal), oestrogen
receptor status (present vs absent) and disease-free interval (p24
months vs 424 months) (Honig, 1996; Yamamoto et al, 1998).
Using a model in which all these factors were maintained, IL-6
remained an additional independent prognostic factor for survival.
This was confirmed on introducing serum IL-6 levels as a
continuous variable (Po0.001, hazard ratio [HR]¼1.02), or when
the different threshold values were tested (Table 2): IL-6
X8pgml
 1 (P¼0.007, HR¼2), IL-6 X13pgml
 1 (Po0.001,
HR¼3.2), IL-6 X30pgml
 1 (P¼0.001, HR¼3) and IL-6
X55pgml
 1 (Po0.001, HR¼5.2).
DISCUSSION
There is accumulating evidence that the serum levels of angiogenic
factors have prognostic significance in human cancers of epithelial
or hematological origin (Poon et al, 2001). In this study, we have
evaluated the clinical significance of serum VEGF and IL-6 levels
on 87 metastatic breast cancer patients.
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Figure 2 Survival of patients as a function of serum IL-6 levels. Patients
with high levels of serum IL-6 constituted a subgroup of very poor
prognosis. The cutoff value (55pgml
 1) represents the highest quartile for
serum IL-6 levels when detectable.
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Figure 1 Correlation of plasma VEGF and serum VEGF in metastatic
breast cancer patients (r¼0.74, Po0.001).
Table 2 Results of the multivariate analysis: significant factors and
associated hazard ratio (HR)
Factor P-value HR
95% confidence
interval of HR
PS41 o0.001 3.1 1.8–5.6
IL-6X8pgml
 1 0.007 2.2 1.2–3.8
Prior adjuvant chemotherapy 0.002 2 1.4–4.7
PS¼performance status.
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patients have elevated serum levels of VEGF as compared with
normal controls, as well as with women with primary breast
cancer. Three of those studies, performed with the same immuno-
assay as the one we used, reported median serum VEGF levels
ranging from 186 to 368pgml
 1, with a considerable range
between minimum and maximum levels (10 to 2426pgml
 1 in the
series of Kraft et al, 1999) (Salven et al, 1999b; Adams et al, 2000).
These results are consistent with our findings (median:
302pgml
 1; range 31–3183) confirming the strong correlation
between serum VEGF and platelet count (Salgado et al, 1999). In
this series, the median platelet VEGF concentration, estimated
from the ratio between serum VEGF and platelet count, was
1.5pg10
 6 platelets, which is in agreement with results obtained
in other series of metastatic cancer patients (Salgado et al,
1999; Salven et al, 1999a). Furthermore, we have confirmed
the correlation between platelet VEGF concentration and IL-6
levels, thus placing further emphasis on the importance of IL-6
on VEGF metabolism (Vermeulen et al, 1999; Salgado et al,
2002).
As most serum VEGF is released from platelets during blood
clotting, plasma VEGF may be a better reflection of ongoing
angiogenesis and, accordingly, a better prognostic marker for
patients with cancer (Banks et al, 1998). To test this hypothesis, we
assessed plasma VEGF levels in 73 of our patients for whom an
EDTA plasma sample had been collected at the same time as the
serum sample. We found that plasma VEGF is strongly correlated
to serum VEGF and to platelet count, which is in agreement
with previous findings on colorectal cancer patients (George et al,
2000; Werther et al, 2002). With regard to survival, plasma VEGF
levels were not related to prognosis in this subgroup of 73 patients.
The strong correlation between serum and plasma VEGF may
reflect the fact that plasma VEGF levels are directly related to
total blood VEGF levels and correspond to free VEGF after
equilibration with platelet levels (George et al, 2000). Alternatively,
we cannot rule out that the platelet VEGF released following a
partial platelet degradation during plasma sampling and storage,
may account for part of the EDTA plasma VEGF (Wynendaele et al,
1999).
In our series, only 39% patients had detectable levels of IL-6,
which is less than previously reported and may be because of the
low sensitivity of the ELISA kit we used (detection limit: 8pgml
 1)
(Salgado et al, 1999; Zhang and Adachi, 1999). We could not find
any correlation between serum IL-6 and platelet numbers nor
between serum IL-6 and VEGF levels, and this result was
maintained when the analysis was restricted to patients who had
not received any chemotherapy for their metastatic disease.
With regard to survival, the present results show that high
serum IL-6 levels are associated with a poor overall survival, while
serum and plasma VEGF levels do not significantly correlate to the
outcome. Results of the multivariate analysis show that IL-6 levels
remain independent variables for survival when assessed with
clinical prognostic markers.
No studies to date have shown any correlation between the
survival of metastatic breast cancer patients and serum or plasma
levels of VEGF, which is in contrast with several other publications
reporting a strong correlation between VEGF expression in the
tumour and prognosis in early-stage breast cancers (Gasparini,
2000; Manders et al, 2002). Different factors might account for the
lack of prognostic value of VEGF in our series. Breast cancer is a
heterogeneous disease with variable biological and clinical
behaviours, in which clinical evolution is much less predictable
than in lymphoma or metastatic renal cell carcinoma. Serum VEGF
may reflect the disease status at a given time (i.e. stable or
progressive) and fail to mirror important biological properties,
such as sensitivity to chemotherapy or to hormone manipulation,
that will ultimately be of utmost importance for prognosis (Honig,
1996). This hypothesis is supported by the work of Dirix et al
(1997), who have reported that the positive association of a short
tumour volume-doubling time with elevated bFGF and VEGF
serum levels in advanced cancer patients is largely independent
from the metastatic pattern and the extent of the disease. An
alternative explanation may be the relative importance of VEGF, as
compared to other angiogenic factors, in metastatic breast cancer.
In a model of human breast carcinoma xenografted into nude
mice, VEGF was shown to be critical for tumorigenesis, but not for
growth, after the tumours had reached a certain size (Yoshiji et al,
1997). The authors hypothesised that VEGF downregulation might
be balanced by bFGF, TGFa or other angiogenic factors. In
metastatic breast cancer, angiogenesis may thus depend on
numerous redundant angiogenic factors whose relative importance
varies from one patient to another and/or during the evolution of
the disease.
Since IL-6 induces VEGF transcription and augments both
platelet production and platelet storage of VEGF, it was formerly
hypothesised that IL-6 could be regarded as an indirect angiogenic
factor acting mainly on VEGF metabolism (Salgado et al, 1999;
Vermeulen et al, 1999). Results presented here do not support this
hypothesis. We have confirmed the relation between platelet VEGF
content and IL-6, but we have failed to show any association
between survival and VEGF, or between survival and platelet VEGF
content. On the other hand, the serum level of IL-6 is an
independent prognosis factor, which confirms results obtained by
Zhang et al on a smaller series (Zhang and Adachi, 1999). This
suggests that, apart from the regulatory effects of IL-6 on VEGF
production, other mechanisms are responsible for the deleterious
effects of high serum IL-6 levels on tumour growth, thus
explaining their strong correlation with prognosis in metastatic
breast cancer patients. Although IL-6 expression in early-stage
breast carcinomas has been correlated with low grade, oestrogen
receptor status and good prognosis (Fontanini et al, 1999;
Karczewska et al, 2000), several studies have shown that IL-6
may contribute to disease progression, particularly in advanced
breast cancer patients. Indeed, IL-6 can modulate steroid hormone
responsiveness by increasing aromatase activity and oestradiol 17
beta-hydroxysteroid dehydrogenase activity in malignant tissue
and by activating oestrogen receptor-a (Duncan et al, 1994; Singh
et al, 1999; Speirs et al, 2000). IL-6 may promote cell migration by
activating the mitogen-dependent protein kinase pathway, and
increase chemotherapeutic resistance by inhibiting the activation
of proteases involved in apoptosis (Lotem and Sachs, 1997;
Badache and Hynes, 2001). Finally, IL-6 promotes osteoclast
formation and inhibits dendritic cell differentiation, thus facilitat-
ing metastatic growth (Menetrier-Caux et al, 1998; Grano et al,
2000). As tumours evolve toward a metastatic phenotype and
interfere with other endogenous or exogenous factors, IL-6 activity
on cancer cells and their environment might actually shift from
growth inhibition and differentiation to proliferation and anti-
apoptosis (Lu and Kerbel, 1993; Chiu et al, 1996; Badache and
Hynes, 2001). This could explain the favourable prognosis
associated with the presence of tumour IL-6 in early-stage breast
cancer (Karczewska et al, 2000) and the poor survival associated
with high serum IL-6 levels in this series of metastatic breast
cancer patients. It is noteworthy that, as in early-stage breast
cancer, IL-6 functions as an inhibitor of cancer cell growth in
benign prostate hyperplasia (Degeorges et al, 1996), but is
correlated with a poor survival in stage-D prostate cancer
(Nakashima et al, 2000).
Finally, as no serum acute-phase protein levels were assessed in
this study, we cannot rule out that IL-6 serum levels in this
population may merely be associated with a generalised inflam-
matory response to metastatic disease. IL-6 has been shown to be
involved in the physiopathology of paraneoplastic inflammatory
syndromes observed in patients with renal-cell carcinoma; a
similar phenomenon might occur in metastatic breast cancer
patients (Blay et al, 1997).
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independently correlated to survival in a relevant population of
metastatic breast cancer patients. Our results suggest that IL-6
plays an important role in metastatic breast carcinoma progression
in vivo. If confirmed on a larger, prospective study, this might
prove helpful in identifying patients with a particularly poor
prognosis, which is of utmost importance when planning therapy.
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